Edmund Harrigan
Director/Board Member bij ACADIA PHARMACEUTICALS INC.
Vermogen: 1 M $ op 31-03-2024
Profiel
Edmund P.
Harrigan is an Independent Director at Incyte Corp., ACADIA Pharmaceuticals, Inc., PhaseBio Pharmaceuticals, Inc., and AlgoTherapeutix SAS.
He previously served as an Independent Director at Bellicum Pharmaceuticals, Inc. from 2018 to 2019, an Independent Non-Executive Director at Karuna Therapeutics, Inc. from 2011 to 2020, and as a Senior VP-Worldwide Safety & Regulatory at Pfizer Inc. from 2012 to 2015.
Harrigan's education includes an undergraduate degree from St. Anselm College in 1974 and a doctorate degree from UMass Chan Medical School in 1979.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
INCYTE CORPORATION
0.01% | 28-03-2024 | 13 115 ( 0.01% ) | 747 162 $ | 31-03-2024 |
01-06-2023 | 19 002 ( 0.01% ) | 351 347 $ | 31-03-2024 | |
19-05-2023 | 9 750 ( 0.02% ) | - $ | 31-01-2024 |
Actieve functies van Edmund Harrigan
Bedrijven | Functie | Begin |
---|---|---|
ACADIA PHARMACEUTICALS INC. | Director/Board Member | 25-11-2015 |
PHASEBIO PHARMACEUTICALS, INC. | Director/Board Member | 13-12-2018 |
INCYTE CORPORATION | Director/Board Member | 16-12-2019 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Director/Board Member | 13-04-2021 |
Eerdere bekende functies van Edmund Harrigan
Bedrijven | Functie | Einde |
---|---|---|
KARA THER | Director/Board Member | 03-12-2020 |
BELLICUM PHARMACEUTICALS, INC. | Director/Board Member | 19-12-2019 |
PFIZER, INC. | General Counsel | 01-07-2015 |
Lyndra Therapeutics, Inc.
Lyndra Therapeutics, Inc. Packaged SoftwareTechnology Services Lyndra Therapeutics, Inc. develops software technology for oral drug formulations. It offers pharmacology, therapeutic impact, reduced pill burden, and reduced care giver burden. The company was founded by Amy W. Schulman, Carlo Giovanni Traverso, Andrew Bellinger, and Robert S. Langer Jr. in 2015 and is headquartered in Watertown, MA. | Director/Board Member | - |
Opleiding van Edmund Harrigan
St. Anselm College | Undergraduate Degree |
UMass Chan Medical School | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
INCYTE CORPORATION | Health Technology |
PFIZER, INC. | Health Technology |
ACADIA PHARMACEUTICALS INC. | Health Technology |
PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA. | Health Technology |
Lyndra Therapeutics, Inc.
Lyndra Therapeutics, Inc. Packaged SoftwareTechnology Services Lyndra Therapeutics, Inc. develops software technology for oral drug formulations. It offers pharmacology, therapeutic impact, reduced pill burden, and reduced care giver burden. The company was founded by Amy W. Schulman, Carlo Giovanni Traverso, Andrew Bellinger, and Robert S. Langer Jr. in 2015 and is headquartered in Watertown, MA. | Technology Services |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Health Technology |